Physician profile
Noureen Akbar
NPI 1306138623
$1,413.81
in general payments reported to CMS, 2019-2025
19 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $336 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $365.22 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.94 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $133.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $119.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $115.62 | 2019-2020 | |
| Astellas Pharma US INC | $75.36 | 2019 | |
| Glaxosmithkline, LLC. | $62.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.18 | 2019 | |
| Gilead Sciences, INC. | $40.22 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.05 | 2019 | |
| Amgen INC. | $35.80 | 2019 | |
| Lilly USA, LLC | $33.92 | 2019-2020 | |
| Phadia US INC. | $32.50 | 2019-2020 | |
| Amarin Pharma, INC. | $30.89 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $24.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $20.42 | 2019 | |
| Pfizer INC. | $17.14 | 2019 | |
| Daiichi Sankyo INC. | $12.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noureen Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.